International
Blood plasma from patients who have recovered from COVID-19, called convalescent plasma, does not prevent disease progression when it is given to high-risk outpatients within 1 week after the onset of symptoms of Covid-19. It had been hoped that early administration of convalescent plasma may prevent disease progression in acutely ill, high-risk patients with Covid-19, however the study of over 500 patients showed no benefit. Disease progression occurred in 77 patients who received convalescent-plasma compared to 81 patients who received placebo. Five patients in the plasma group and 1 patient in the placebo group died. Outcomes regarding worst illness severity and hospital-free days were similar in the two groups.
From:
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
